Health Care·Biotechnology·$8.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.74 | N/A | +0.40% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.74 | N/A | +0.40% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management remains focused on advancing their product pipeline. They acknowledged the challenges but emphasized their commitment to innovation.
Management highlighted ongoing research and development efforts.
They expressed confidence in their pipeline despite current losses.
Krystal Biotech's earnings report showed a narrower-than-expected loss per share, which contributed to a slight increase in stock price. Investors may be encouraged by management's focus on R&D and their commitment to future growth, despite the lack of revenue figures and guidance. The stock's positive reaction suggests that the market is cautiously optimistic about the company's direction.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
LIBERTY MEDIA CORP D Series A
Aug 6, 2021